Krabbe Disease Pipeline is Expected to Show a Healthy Growth Rate During the Study Period (2019-2032)| Key Companies -Mylan Pharmaceuticals, UCB Pharmaceuticals, Astellas Pharmaceuticals

DelveInsight's, "Krabbe Disease - Pipeline Insight, 2023," report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in Krabbe Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Download Sample Report to know more @https://www.delveinsight.com/sample-request/krabbe-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Krabbe Disease Overview
Krabbe disease comprises a spectrum ranging from infantile-onset disease (i.e., onset of extreme irritability, spasticity, and developmental delay before age 12 months) to later-onset disease (i.e., onset of manifestations after age 12 months and as late as the seventh decade). Although historically 85%-90% of symptomatic individuals with Krabbe disease diagnosed by enzyme activity alone have infantile-onset Krabbe disease and 10%-15% have later-onset Krabbe disease, the experience with newborn screening (NBS) suggests that the proportion of individuals with possible later-onset Krabbe disease is higher than previously thought. Infantile-onset Krabbe disease is characterized by normal development in the first few months followed by rapid severe neurologic deterioration; the average age of death is 24 months (range 8 months to 9 years). Later-onset Krabbe disease is much more variable in its presentation and disease course.

Click here to learn more about the Krabbe Disease Pipeline Landscape @https://www.delveinsight.com/sample-request/krabbe-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Key Highlights
The pharmaceutical companies working for Krabbe Disease includes Forge Biologics, Passage Bio, Sanbio, Polaryx, Gain Therapeutics, and many others
The Key Therapies working in the Krabbe Disease includes PBKR03, FBX-101, Cyclophosphamide and many others

Learn more about the treatment market for Krabbe Disease @ https://www.delveinsight.com/report-store/krabbe-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

DelveInsight's report covers around 8+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued and inactive candidates
Route of Administration
Krabbe Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Intravenous
Subcutaneous
Molecule Type
Products have been categorized under various Molecule types such as
Small molecule
Cell Therapy
Peptides
Polymer
Small molecule
Gene therapy
Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
Lean more @https://www.delveinsight.com/report-store/krabbe-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

Table of Contents
Key Insights
Krabbe Disease Introduction
Executive Summary of Krabbe Disease
Disease Background and Overview
Krabbe Disease Epidemiology and patient population
Krabbe Disease Emerging Therapies
Krabbe Disease Pipeline Outlook
Krabbe Disease Pipeline Access and Reimbursement of Therapies
Krabbe Disease Pipeline Drivers
Krabbe Disease Pipeline Barriers
Appendix
Krabbe Disease Report Methodology
DelveInsight Capabilities
Disclaimer

Learn about the detailed offerings of the Krabbe Disease Market Outlook report @ https://www.delveinsight.com/report-store/krabbe-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr

DelveInsight Business Research LLP
Adya Kaul
info@delveinsight.com
https://www.delveinsight.com

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.